Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024

Rhea-AI Summary

Altamira Therapeutics (Nasdaq: CYTO), a company specializing in nanoparticle-based RNA delivery technology, has announced its upcoming First Half 2024 Financial Results and Business Update Call. The event is scheduled for Tuesday, September 24, 2024, at 8:30 am ET.

Key participants in the call will be Founder, Chairman, and CEO Thomas Meyer, along with COO Covadonga Pañeda. They will present prepared remarks followed by a Q&A session open to investors and analysts.

Interested parties can access the webcast through the provided URL. Additionally, a registration link is available for those who wish to join the call via phone. Multiple options for joining are offered, including dial-in with a unique PIN and a 'Call Me' feature. A replay of the call will be accessible through the webcast link after the live event concludes.

News Market Reaction

-5.31%

1 alert

-5.31% News Effect

On the day this news was published, CYTO declined 5.31%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its First Half 2024 Financial Results and Business Update Call on Tuesday, September 24, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts.

Webcast Access:

• Event: Altamira Therapeutics First Half 2024 Financial Results and Business Update Call
• Date: Tuesday, September 24, 2024
• Time: 8:30 am ET
• Webcast URL: https://edge.media-server.com/mmc/p/4wp8659n

Registration for Call:

https://register.vevent.com/register/BI039aac00f0eb4f228e9662f9b90a1ea4

• Click on the call link and complete the online registration form.
• Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
• Select a method for joining the call:
  • Dial-In: A dial in number and unique PIN are displayed to connect directly from your phone.
  • Call Me: Enter your phone number and click “Call Me” for an immediate callback from the system. The call will come from a US number. 

A replay of the call will be available after the live event and accessible through the webcast link:
https://edge.media-server.com/mmc/p/4wp8659n

About Altamira Therapeutics

Altamira Therapeutics (Nasdaq: CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets (AM-125 nasal spray for vertigo; post Phase 2; Keyzilen® and Sonsuvi® for tinnitus and hearing loss; Phase 3). Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com

Investor Contact

Hear@altamiratherapeutics.com

FAQ

When is Altamira Therapeutics (CYTO) hosting its First Half 2024 Financial Results call?

Altamira Therapeutics (CYTO) is hosting its First Half 2024 Financial Results and Business Update Call on Tuesday, September 24, 2024, at 8:30 am ET.

Who will be presenting during Altamira Therapeutics' (CYTO) financial results call?

Founder, Chairman, and CEO Thomas Meyer, along with COO Covadonga Pañeda, will be delivering prepared remarks and answering questions during the call.

How can investors access Altamira Therapeutics' (CYTO) First Half 2024 Financial Results call?

Investors can access the call via webcast, dial-in with a unique PIN, or use the 'Call Me' feature after registering through the provided link.

Will there be a replay available for Altamira Therapeutics' (CYTO) financial results call?

Yes, a replay of the call will be available after the live event and can be accessed through the provided webcast link.